GoAI
Get started
Syndax Pharmaceuticals, Inc. logo

Syndax Pharmaceuticals, Inc.

SNDX

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$19.65

−$0.10 · -0.51%

Aug 21, 4:00 PM ET

SNDX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

30

Expensive

Momentum

70

Gaining

Sentiment

60

Mixed

Risk resilience

66

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Syndax Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on developing innovative therapies for cancer. Among its leading investigational products are SNDX-5613, currently undergoing Phase 1/2 clinical assessment, which targets the Menin-mixed lineage leukemia 1 protein interaction for treating MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML). Another significant candidate is SNDX-6352, or axatilimab, a monoclonal antibody designed to block the colony stimulating factor 1 (CSF-1) receptor, intended for patients suffering from chronic graft versus host disease (cGVHD). The company is additionally progressing Entinostat. Syndax has also established strategic collaborations, including a research and development agreement with the National Cancer Institute, a clinical trial agreement with the Eastern Cooperative Oncology Group, and a license agreement with Kyowa Hakko Kirin Co., Ltd. Founded in 2005, Syndax Pharmaceuticals, Inc. maintains its corporate headquarters in Waltham, Massachusetts.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Michael A. Metzger
Listed since
Mar 2, 2016
Employees
298

Market position

Day range

Current $19.65

52-week range

Current $19.65

Open
$19.93
Previous close
$19.75
Volume
1.7M
0.96× average
Average volume
1.77M
Average daily volume
Market cap
1.74B USD
Beta
0.37
Market reference 1
50-day average
$20.7303
-5.21% below average
200-day average
$20.7746
-5.41% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
2.03B USD
P/E (TTM)
-7.8×
P/B (TTM)
115.81×
P/S (TTM)
6.91×
EV / EBITDA
-8.07×
Earnings yield
-15.68%
Free cash flow yield
-17.76%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
97.47%
Operating margin
-77.05%
Net margin
-87.60%
Return on equity
-441.62%
Return on assets
-53.88%
Return on invested capital
-66.60%

Financial health

Debt / equity
39.03×
Current ratio
4.4×
Altman Z-score
-0.96
Piotroski F-score
3 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends253%-360%-974%-1588%Gross margin, FY2021: 100.00%Gross margin, FY2024: 96.51%Gross margin, FY2025: 95.96%Operating margin, FY2021: 18.77%Operating margin, FY2024: -1434.43%Operating margin, FY2025: -158.45%Net margin, FY2021: 17.84%Net margin, FY2024: -1346.11%Net margin, FY2025: -165.60%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 100.00%. Gross margin FY2024 96.51%. Gross margin FY2025 95.96%. Operating margin FY2021 18.77%. Operating margin FY2024 -1434.43%. Operating margin FY2025 -158.45%. Net margin FY2021 17.84%. Net margin FY2024 -1346.11%. Net margin FY2025 -165.60%.

Income trends

Revenue

172.35M USD+627.84%

Operating income

−273.08M USD+19.60%

Net income

−285.42M USD+10.46%
Income trends across reported periods223.55M USD18.74M USD−186.06M USD−390.87M USDRevenue, FY2021: 139.71M USDRevenue, FY2024: 23.68M USDRevenue, FY2025: 172.35M USDOperating income, FY2021: 26.22M USDOperating income, FY2022: −151.76M USDOperating income, FY2023: −229.95M USDOperating income, FY2024: −339.67M USDOperating income, FY2025: −273.08M USDNet income, FY2021: 24.93M USDNet income, FY2022: −149.34M USDNet income, FY2023: −209.36M USDNet income, FY2024: −318.76M USDNet income, FY2025: −285.42M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 139.71M USD. Revenue FY2024 23.68M USD. Revenue FY2025 172.35M USD. Operating income FY2021 26.22M USD. Operating income FY2022 −151.76M USD. Operating income FY2023 −229.95M USD. Operating income FY2024 −339.67M USD. Operating income FY2025 −273.08M USD. Net income FY2021 24.93M USD. Net income FY2022 −149.34M USD. Net income FY2023 −209.36M USD. Net income FY2024 −318.76M USD. Net income FY2025 −285.42M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue172.35M USD23.68M USD——139.71M USD
Cost of goods sold6.97M USD826K USD———
Gross profit165.38M USD22.85M USD——139.71M USD
Research and development258.78M USD241.65M USD163.03M USD118.5M USD88.25M USD
Selling, general, and administrative179.68M USD120.88M USD66.92M USD33.26M USD25.24M USD
Operating expenses438.47M USD362.53M USD229.95M USD151.76M USD113.49M USD
Interest income22.73M USD26.09M USD21.16M USD5.87M USD403K USD
Interest expense33.79M USD4.93M USD208K USD3.14M USD1.9M USD
Depreciation and amortization6K USD8K USD12K USD33K USD43K USD
Operating income−273.08M USD−339.67M USD−229.95M USD−151.76M USD26.22M USD
Net income−285.42M USD−318.76M USD−209.36M USD−149.34M USD24.93M USD

Company facts updated Aug 24, 2026.

Earnings

Latest fiscal-year EPS
-3.29
FY2025
Latest fiscal-year revenue
172.35M USD
FY2025 · +627.84% year over year
Next fiscal-year EPS consensus
-1.98
FY2026 · 8 analysts
Next fiscal-year revenue consensus
316.14M USD
FY2026 · 8 analysts

Annual EPS trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual EPS trend2.30.11-2.09-4.28FY21FY22FY23FY24FY25FY26FY27FY28

Annual revenue trend

Reported history and fiscal-year consensus

ReportedConsensus forecast
Annual revenue trend896.56M570.54M244.52M-81.51MFY21FY22FY23FY24FY25FY26FY27FY28

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$37.00

88.30% upside
Past 12 months12-month forecastHigh $46.00Average $37.00Low $31.00

Recent analyst actions

12 institutions

SNDX news

globenewswire.com

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

NEW YORK, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on August 1, 2026, the Company…

Read source
seekingalpha.com

Syndax Pharmaceuticals, Inc. (SNDX) Q2 2026 Earnings Call Transcript

Syndax Pharmaceuticals, Inc. (SNDX) Q2 2026 Earnings Call Transcript

Read source
marketbeat.com

Syndax Pharmaceuticals Q2 Earnings Call Highlights

Syndax Pharmaceuticals NASDAQ: SNDX reported second-quarter 2026 total revenue of $72.8 million, up 92% from the prior-year period, as sales of its leukemia treatment Revuforj and chronic graft-versus-host disease…

Read source
zacks.com

Syndax Pharmaceuticals (SNDX) Reports Q2 Loss, Lags Revenue Estimates

Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.55 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to a loss of $0.83 per share a year ago.

Read source
globenewswire.com

Syndax Reports Second Quarter 2026 Financial Results and Provides Business Update

– Total revenue of $73 million in 2Q26, a 92% year-over-year increase – – Revuforj ® (revumenib) net revenue of $54.7 million in 2Q26, a 91% year-over-year increase – – Niktimvo™ (axatilimab-csfr) net revenue of $60.3…

Read source
globenewswire.com

Syndax to Announce Second Quarter 2026 Financial Results and Host Conference Call and Webcast on August 4, 2026

NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that it will report its second…

Read source

SNDX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding SNDX

Funds reporting this stock among their holdings, ordered by reported position size.

State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
72.93M
Weight
0.64%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$165.73+1.44%
Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
54.1M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$378.24+0.44%
iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
45.03M
Weight
0.06%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$299.96+0.77%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
19.47M
Weight
0.02%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$245.53+0.82%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
16.23M
Weight
0.11%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$387.37+1.24%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
11.88M
Weight
0.11%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$213.56+1.29%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
9.52M
Weight
0.05%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$121.25+0.74%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
8.39M
Weight
0.04%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.83+0.52%

Continue in GoAI

Research SNDX

research.disclaimer